Literature DB >> 19936940

A history of biopharmaceutics in the Food and Drug Administration 1968-1993.

Jerome Philip Skelly1.   

Abstract

The history of biopharmaceutics is reviewed, beginning with its origin out of the Division of Clinical Research in The Bureau of Medicine. The reason for the creation of the Division of Biopharmaceutics, the certification of Food and Drug Administration authority over the functions it was to have, and the implementation of that authority are described. The determination of bioequivalence, the bioavailability decision rules, pharmacokinetics, and drug metabolism are explained. The reason for the development of the Scale-Up and Post Approval Regulations and how they were developed are also explained.

Mesh:

Substances:

Year:  2009        PMID: 19936940      PMCID: PMC2811644          DOI: 10.1208/s12248-009-9154-8

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  15 in total

1.  In vivo percutaneous penetration/absorption, Washington, D.C., May 1989.

Authors:  V P Shah; G L Flynn; R H Guy; H I Maibach; H Schaefer; J P Skelly; R C Wester; A Yacobi
Journal:  Pharm Res       Date:  1991-08       Impact factor: 4.200

2.  Consideration of individual bioequivalence.

Authors:  S Anderson; W W Hauck
Journal:  J Pharmacokinet Biopharm       Date:  1990-06

3.  A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability.

Authors:  D J Schuirmann
Journal:  J Pharmacokinet Biopharm       Date:  1987-12

4.  Are generic formulations equivalent to trade name topical glucocorticoids?

Authors:  R B Stoughton
Journal:  Arch Dermatol       Date:  1987-10

5.  Drug bioequivalence. Recommendations from the Drug Bioequivalence Study Panel to the Office of Technology Assessment, Congress of the United States.

Authors: 
Journal:  J Pharmacokinet Biopharm       Date:  1974-10

6.  Variation in biologic availability of digoxin from four preparations.

Authors:  J Lindenbaum; M H Mellow; M O Blackstone; V P Butler
Journal:  N Engl J Med       Date:  1971-12-09       Impact factor: 91.245

7.  An evaluation of the absorption characteristics of different chloramphenicol preparations in normal human subjects.

Authors:  A J Glazko; A W Kinkel; W C Alegnani; E L Holmes
Journal:  Clin Pharmacol Ther       Date:  1968 Jul-Aug       Impact factor: 6.875

8.  Assessment of the biologic availability of tetracycline products in man.

Authors:  W H Barr; L M Gerbracht; K Letcher; M Plaut; N Strahl
Journal:  Clin Pharmacol Ther       Date:  1972 Jan-Feb       Impact factor: 6.875

9.  Tetracycline. Another example of generic bioinequivalence.

Authors:  J H Wood; K P Flora; R J Duma
Journal:  JAMA       Date:  1978-05-05       Impact factor: 56.272

10.  Food-induced "dose-dumping" from a once-a-day theophylline product as a cause of theophylline toxicity.

Authors:  L Hendeles; M Weinberger; G Milavetz; M Hill; L Vaughan
Journal:  Chest       Date:  1985-06       Impact factor: 9.410

View more
  1 in total

1.  The Study of Prescribing Errors Among General Dentists.

Authors:  Solmaz Araghi; Rohollah Sharifi; Goran Ahmadi; Mahsa Esfehani; Fatemeh Rezaei
Journal:  Glob J Health Sci       Date:  2015-07-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.